PDF(Pubmed)
Abstract：
Hepatocellular carcinoma (HCC) ranks as the sixth most common malignancy globally, with the majority of patients presenting at the initial diagnosis with locally advanced or metastatic disease, precluding the opportunity for curative surgical intervention. With the exploration and advancement of locoregional treatments, novel molecular-targeted therapies, anti-angiogenic agents, and immunomodulatory drugs, the management of HCC has seen an increase in objective response rates and prolonged duration of response significantly enhancing the potential for conversion to resectable disease in intermediate and advanced-stage unresectable HCC. Herein, we present a case of Barcelona Clinic Liver Cancer stage B unresectable HCC, where after two courses of treatment with transarterial chemoembolization combined with atezolizumab plus bevacizumab significant tumor reduction was achieved. Per Response Evaluation Criteria in Solid Tumors 1.1, partial response culminated in successful curative surgical resection. No drug-related adverse reactions occurred during hospitalization, and there has been no recurrence during the 11-month postoperative follow-up. For patients with Barcelona Clinic Liver Cancer stage B (intermediate-stage) unresectable HCC, the transarterial chemoembolization combined with atezolizumab plus bevacizumab regimen may offer improved therapeutic outcomes leading to a higher success rate of conversion therapy and, thus, improved survival.
摘要：
肝细胞癌（HCC）是全球第六大最常见的恶性肿瘤，大多数患者在最初诊断为局部晚期或转移性疾病，排除了治愈性手术干预的机会。随着局部治疗的探索和进步，新型分子靶向疗法，抗血管生成剂，和免疫调节药物，在HCC的治疗中,客观缓解率提高,缓解持续时间延长,显著增强了中晚期不可切除HCC患者转诊为可切除疾病的可能性.在这里，我们介绍了巴塞罗那临床肝癌B期不可切除的HCC，经动脉化疗栓塞联合阿特珠单抗加贝伐单抗治疗两个疗程后,肿瘤显著减少.根据实体瘤的反应评估标准1.1，部分反应最终导致成功的治愈性手术切除。住院期间无药物相关不良反应发生,在术后11个月的随访中没有复发。对于巴塞罗那临床肝癌B期（中期）不可切除的HCC患者，经肝动脉化疗栓塞联合阿特珠单抗加贝伐单抗方案可改善治疗结果，从而提高转换治疗的成功率，因此，改善生存。
